Stiftung Marie-Lou Ringgenberg Bern Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2016
NCT02776514
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

hyaluronic acid (1 trial)

platelet-rich plasma (1 trial)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3